Antagonism of NF-κB-up-regulated micro RNAs (miRNAs) in sporadic Alzheimer's disease (AD)-anti-NF-κB vs. anti-miRNA strategies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

1. The neuroinflammatory role of microRNAs in Alzheimer's disease: pathological insights to therapeutic potential.Molecular and cellular biochemistry · 2025
   Review
2. TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer's Disease.International journal of molecular sciences · 2023
   Article
3. Emerging Roles of Non-Coding RNAs in Childhood Asthma.Frontiers in pharmacology · 2022
   Review
4. Chromosome 21-Encoded microRNAs (mRNAs): Impact on Down's Syndrome and Trisomy-21 Linked Disease.Cellular and molecular neurobiology · 2018
   Article
5. microRNAs in Neurodegeneration: Current Findings and Potential Impacts.Journal of Alzheimer's disease & Parkinsonism · 2018
   Article
6. A microRNA cluster (let-7c, miRNA-99a, miRNA-125b, miRNA-155 and miRNA-802) encoded at chr21q21.1-chr21q21.3 and the phenotypic diversity of Down's syndrome (DS; trisomy 21).Journal of nature and science · 2017
   Article
7. Anti-microRNAs as Novel Therapeutic Agents in the Clinical Management of Alzheimer's Disease.Frontiers in neuroscience · 2016
   Article
8. MicroRNA (miRNA) Signaling in the Human CNS in Sporadic Alzheimer's Disease (AD)-Novel and Unique Pathological Features.International journal of molecular sciences · 2015
   Article
9. Beta-Amyloid Precursor Protein (βAPP) Processing in Alzheimer's Disease (AD) and Age-Related Macular Degeneration (AMD).Molecular neurobiology · 2015
   Review
10. Induction of the pro-inflammatory NF-kB-sensitive miRNA-146a by human neurotrophic viruses.Frontiers in microbiology · 2015
    Article
11. Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.Frontiers in molecular neuroscience · 2015
    Article
12. Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer's disease (AD) and in primary human neuronal-glial (HNG) cells.Molecular neurobiology · 2014
    Review
13. Human metapneumovirus infection induces significant changes in small noncoding RNA expression in airway epithelial cells.Molecular therapy. Nucleic acids · 2014
    Article
14. Deficits in the miRNA-34a-regulated endogenous TREM2 phagocytosis sensor-receptor in Alzheimer's disease (AD); an update.Frontiers in aging neuroscience · 2014
    Article
15. Regulating amyloidogenesis through the natural triggering receptor expressed in myeloid/microglial cells 2 (TREM2).Frontiers in cellular neuroscience · 2014
    Article
16. Expression of the phagocytosis-essential protein TREM2 is down-regulated by an aluminum-induced miRNA-34a in a murine microglial cell line.Journal of inorganic biochemistry · 2013
    Article
17. TREM2 signaling, miRNA-34a and the extinction of phagocytosis.Frontiers in cellular neuroscience · 2013
    Article
18. Variability in micro RNA (miRNA) abundance, speciation and complexity amongst different human populations and potential relevance to Alzheimer's disease (AD).Frontiers in cellular neuroscience · 2013
    Article
19. From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach.Alzheimer's & dementia (Amsterdam, Netherlands)
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.